Pfizer Inc. $PFE Shares Sold by Heritage Investors Management Corp

Heritage Investors Management Corp decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 311,647 shares of the biopharmaceutical company’s stock after selling 22,755 shares during the quarter. Heritage Investors Management Corp’s holdings in Pfizer were worth $8,888,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Bank of America Corp DE acquired a new position in shares of Pfizer during the 2nd quarter valued at $1,049,602,000. BlackRock Inc. boosted its stake in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares in the last quarter. Nykredit A S acquired a new position in shares of Pfizer during the second quarter valued at about $205,774,000. Assenagon Asset Management S.A. raised its holdings in shares of Pfizer by 96.0% during the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock valued at $286,609,000 after purchasing an additional 5,829,204 shares during the period. Finally, State Street Corp boosted its position in shares of Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after purchasing an additional 5,501,032 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on PFE shares. BMO Capital Markets reduced their target price on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Cantor Fitzgerald increased their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Finally, JPMorgan Chase & Co. raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Five research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.65.

Pfizer Stock Performance

PFE opened at $30.48 on Monday. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $30.67. The company has a market cap of $173.73 billion, a price-to-earnings ratio of 40.11, a PEG ratio of 2.07 and a beta of 0.31. The company’s fifty day moving average price is $28.55 and its two-hundred day moving average price is $26.79. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a yield of 5.6%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.